AffiliationDepartment of Palliative and Supportive Care, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.
MetadataShow full item record
AbstractBladder cancer continues to result in substantial morbidity and mortality for affected individuals. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment. Studies investigating alternative regimes have offered no survival advantage. Targeted therapies may offer benefit either as single agent or in combination with chemotherapy. Symptoms due to metastatic bladder cancer impact patients' quality of life, and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential treatment modalities, and the evidence to support the management strategies.
CitationMetastatic bladder cancer: a review of current management. 2011, 2011:545241 ISRN Urol
- Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
- Authors: Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group.
- Issue date: 2010 Jun
- Bladder cancer: overview and management. Part 2: muscle-invasive and metastatic bladder cancer.
- Authors: Anderson B
- Issue date: 2018 Oct 4
- Bladder cancer.
- Authors: Bischoff CJ, Clark PE
- Issue date: 2009 May
- Current trends in the management of bladder cancer.
- Authors: Patel AR, Campbell SC
- Issue date: 2009 Jul-Aug
- Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
- Authors: Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W
- Issue date: 2014 Jul